10-Q: ResMed Reports Strong Q1 Growth, Profitability Surges

ResMed Inc. announced robust first-quarter fiscal year 2026 results, with net revenue up 9% and diluted earnings per share increasing by 12%, driven by strong demand in Sleep and Breathing Health products and improved gross margins.

Summary

• Net revenue for the three months ended September 30, 2025, increased by 9% to $1,335.6 million, or 8% on a constant currency basis, compared to the same period in the prior year.
• Sleep and Breathing Health net revenue grew by 10% to $1,169.4 million (8% constant currency), primarily due to increased demand and unit sales of devices and masks.
• Residential Care Software net revenue increased by 6% to $166.1 million (5% constant currency), driven by strong growth in the MEDIFOX DAN business vertical, partially offset by weaker performance in Senior Living and Long-Term Care.
• Gross profit rose by 14% to $820.8 million, with gross margin expanding to 61.5% from 58.6% in the prior year, attributed to manufacturing and logistics efficiencies and component cost improvements.
• Net income for the quarter was $348.5 million, a 12% increase from $311.4 million in the prior year.
• Diluted earnings per share (EPS) increased by 12% to $2.37, up from $2.11 in the same period last year.
• Operating expenses increased, including $15.8 million in restructuring charges for employee severance related to workforce planning activities.
• Cash and cash equivalents stood at $1,383.8 million as of September 30, 2025, up from $1,209.5 million at June 30, 2025.
• The effective income tax rate increased to 22.0% from 18.8%, primarily due to global minimum taxes (Pillar Two) and a shift in the global mix of earnings.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant revenue growth, improved gross margins, and increased net income and EPS. Positive legal outcomes further bolster the outlook. While restructuring costs and increased equity investment losses are noted, the overall financial health and operational efficiency improvements indicate a very positive quarter.

Positives

• Net revenue increased by 9% (8% constant currency), indicating strong underlying business growth.
• Sleep and Breathing Health segment showed robust growth of 10% (8% constant currency), driven by high demand for devices and masks.
• Gross margin significantly improved to 61.5% from 58.6%, reflecting enhanced manufacturing and logistics efficiencies and lower component costs.
• Net income and diluted EPS both increased by 12%, demonstrating strong profitability.
• Cash provided by operating activities increased by $131.8 million to $457.3 million, driven by higher net income and improved working capital.
• Interest income, net, turned positive at $8.8 million, compared to an expense of $1.7 million in the prior year, due to lower debt levels.
• A significant legal victory was achieved against New York University, with the Court of Appeals for the Federal Circuit affirming the invalidation of all asserted NYU patents.

Negatives

• Restructuring expenses of $15.8 million were recorded for employee severance and termination benefits, indicating workforce adjustments.
• Loss on equity investments increased to $6.2 million from $0.7 million in the prior year, impacting other income (loss), net.
• The effective income tax rate increased to 22.0% from 18.8%, primarily due to global minimum taxes (Pillar Two) and a shift in the global mix of earnings.
• Cash used in investing activities increased by $54.7 million, primarily due to higher purchases of property, plant, and equipment and net payments from foreign currency contracts.
• Cash used in financing activities increased by $79.5 million, largely due to increased treasury stock repurchases ($150.0 million vs. $50.0 million).

Risks

• Litigation is inherently uncertain, and while current matters are not expected to have a material adverse effect, outcomes could differ from management's expectations.
• Ongoing tax audits by authorities like the Australian Taxation Office could result in material adjustments to past or future taxable income, tax payable, or deferred tax assets, and may incur penalties and interest.
• The calculation of tax liabilities involves uncertainties in the application of complex tax laws, which could lead to material adjustments.
• Exposure to foreign currency market risk due to international operations and transactions in various foreign currencies, despite hedging activities.
• Inflationary factors such as increases in product costs, freight, overhead, or wage rates could adversely affect operating results and gross margins if not offset by price increases.
• The company's ability to execute its growth strategy could be impacted by changes in healthcare reform, macroeconomic conditions, new competitors, supply chain disruptions, and geopolitical factors.

Future Outlook

Management expects current liquidity sources to be sufficient to fund operations, including capital expenditures, for the next 12 months and beyond. The company remains committed to ongoing investment in research and development and product enhancements, focusing on new, innovative products and solutions like the AirSense 11 device, and anticipates continued growth from its Residential Care Software business and robust product pipeline. The company is also evaluating the potential impacts of the OECD's Pillar Two global minimum tax for future periods.

Management Comments

• We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders.
• Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings.
• We are committed to ongoing investment in research and development and product enhancements, with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs.
• Our newest device, AirSense 11, introduced new features such as a touch screen, algorithms for patients new to therapy, digital enhancements, and over-the-air update capabilities.
• Our residential care software platforms, along with our cloud-based remote monitoring and therapy management system, and a robust product pipeline, should continue to provide us with a strong platform for future growth.
• We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.

Industry Context

ResMed operates as a global leader in the medical device industry, specifically targeting sleep-disordered breathing and other respiratory disorders, and the out-of-hospital care software market. The company's strategy aligns with the broader healthcare trend of shifting care from hospitals to lower-cost home settings, leveraging digital cloud-based health software applications and connected devices to improve patient outcomes and operational efficiencies. Increasing awareness of conditions like obstructive sleep apnea and chronic obstructive pulmonary disease continues to fuel market demand for ResMed's products and solutions.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• New York University (NYU) Patent Infringement: The Court of Appeals for the Federal Circuit affirmed the invalidation of all challenged claims in NYU's patents asserted against ResMed on August 8, 2025, effectively ending this litigation in ResMed's favor.
• Cleveland Medical Devices Inc. Patent Infringement (Case 1:22-cv-00794): The District Court stayed the case pending PTAB review. The PTAB found all claims of U.S. Patent No. 10,076,269 unpatentable on May 2, 2025. Cleveland Medical appealed this ruling on August 27, 2025, and the appeal is pending.
• Cleveland Medical Devices Inc. Patent Infringement (Case 23-cv-00500-TWR-JLB): ResMed Corp. is seeking a declaration of non-infringement, while Cleveland Medical counterclaimed for infringement of six additional patents. The District Court stayed this case pending Patent Office proceedings. The PTAB denied review for one patent but instituted Inter Partes Review proceedings for four others, and stayed ex parte reexaminations for two others. Final PTAB decisions are expected by July 2026.
• Fractus, S.A. Patent Infringement (Case 3:25-cv-02680): Fractus filed a new suit on October 9, 2025, alleging infringement of five patents related to antenna technology by ResMed's AirSense, AirCurve devices, and Connectivity Module. Fractus seeks monetary damages, a permanent injunction, and attorneys' fees. ResMed has not yet filed its legal response.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, and a higher dividend declaration. Share repurchase program continues to return capital to shareholders.
• Employees: Impacted by restructuring activities, including severance and termination benefits for workforce planning, which could lead to some job reductions.
• Customers: Benefit from continued investment in research and development, leading to new and innovative products like AirSense 11, and improved efficiencies in residential care software.
• Suppliers: Potential for continued demand for components given increased unit sales, but also pressure for component cost improvements as noted in gross margin expansion.
• Creditors: Debt covenants were in compliance, and liquidity remains strong, indicating low credit risk.

Next Steps

• Continue investment in research and development for new, innovative products and solutions.
• Monitor and evaluate the potential impacts of the OECD's Pillar Two global minimum tax for future periods.
• Address ongoing legal proceedings, including appeals by Cleveland Medical and the newly filed suit by Fractus, S.A.
• The board of directors has declared a cash dividend of $0.60 per common share, payable on December 18, 2025.

Key Dates

Recommendation

ResMed's Q1 2026 results demonstrate robust financial health and operational excellence. The company achieved significant revenue growth across both its Sleep and Breathing Health and Residential Care Software segments, coupled with impressive gross margin expansion driven by efficiency gains. Net income and diluted EPS saw double-digit percentage increases, indicating strong profitability. The substantial increase in cash flow from operations further solidifies its financial position. A key legal victory against NYU removes a significant patent overhang. While restructuring charges and increased equity investment losses are present, they are overshadowed by the overall positive performance and strategic positioning in growing healthcare markets. The company's commitment to R&D and its strong liquidity suggest continued future growth and shareholder value creation, making it a 'strong buy' for investors.

Keywords

Sleep-disordered breathing, Respiratory disorders, CPAP, SaaS, Medical devices, Healthcare technology, Connected care, Obstructive sleep apnea, COPD, Residential care software, Financial results, Earnings, Revenue, Gross margin, SEC filing, 10-Q